https://www.nasdaq.com/press-release/atossa-therapeutics-begins-enrollment-of-phase-2-clinical-study-of-oral-endoxifen-in
https://www.nasdaq.com/press-release/physician-scientist-steven-quay-calls-for-international-effort-to-investigate-a
https://www.nasdaq.com/press-release/atossa-therapeutics-completes-pre-ind-meeting-with-u.s.-food-drug-administration-2021
https://www.nasdaq.com/press-release/registration-is-now-open-for-the-tribe-public-webinar-event-on-november-30-2021-a
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-third-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/atossa-therapeutics-ceo-dr.-steven-quay-emphasizes-importance-of-breast-cancer
https://www.nasdaq.com/press-release/atossa-therapeutics-begins-enrollment-in-clinical-study-of-at-h201-in-australia-2021
https://www.nasdaq.com/press-release/atossa-therapeutics-adjourns-special-stockholder-meeting-to-october-7-2021-to-allow
https://www.nasdaq.com/press-release/atossa-therapeutics-receives-approval-from-the-swedish-ethics-review-authority-to
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-second-quarter-2021-financial-results-provides
https://www.nasdaq.com/press-release/atossa-therapeutics-to-present-at-the-btig-virtual-biotechnology-conference-on-august
https://www.nasdaq.com/press-release/physician-scientist-steven-quay%3a-forensic-examination-of-wuhan-institute-of-virology
https://www.nasdaq.com/press-release/physician-scientist-steven-quay-and-an-international-team-of-scientists-and
https://www.nasdaq.com/press-release/atossa-therapeutics-receives-regulatory-approval-to-open-clinical-study-of-at-h201-in
https://www.nasdaq.com/press-release/atossa-therapeutics-set-to-be-included-in-the-russell-2000-and-russell-3000-indexes
https://www.nasdaq.com/press-release/atossa-therapeutics-receives-approval-from-swedish-regulators-to-initiate-phase-2
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-final-data-from-phase-2-endoxifen-breast-cancer-study
https://www.nasdaq.com/press-release/atossa-therapeutics-to-release-final-data-from-phase-2-study-of-endoxifen
https://www.nasdaq.com/press-release/new-research-demonstrates-claims-that-the-wuhan-institute-of-virology-had-no-cases-of
https://www.nasdaq.com/press-release/physician-scientist-dr.-steven-quay-to-brief-the-u.s.-congress-on-his-research
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-first-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/atossa-therapeutics-to-participate-at-the-investor-summit-conference-and-present-to
https://www.nasdaq.com/press-release/atossa-therapeutics-urges-shareholders-to-vote-on-proposals-ahead-of-its-annual
https://www.nasdaq.com/press-release/atossa-therapeutics-ceo-dr.-steven-quay-to-participate-in-panel-discussion-at-cello
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-ovarian-cancer-patient-has-begun-treatment-with-oral
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-year-end-2020-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/physician-scientist-steven-quay-provides-open-letter-response-to-who-report%3a-five
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-pricing-of-%2450.0-million-registered-direct-offering
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-receipt-of-fda-safe-to-proceed-letter-for-treatment-of
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-final-results-from-phase-1-clinical-study-showing
https://www.nasdaq.com/press-release/atossa-therapeutics-president-and-ceo-dr.-steven-c.-quay-issues-annual-letter-to-0
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-two-year-update-of-fda-approved-expanded-access
https://www.nasdaq.com/press-release/atossa-therapeutics-phase-2-endoxifen-breast-cancer-study-produces-substantially
https://www.nasdaq.com/press-release/atossa-therapeutics-receives-%2421-million-from-recent-exercises-of-outstanding
https://www.nasdaq.com/press-release/new-study-by-dr.-steven-quay-concludes-that-sars-cov-2-came-from-a-laboratory-2021-01
https://www.nasdaq.com/press-release/registration-is-now-open-for-tribe-publics-webinar-event-the-important-role-of-covid
https://www.nasdaq.com/press-release/atossa-therapeutics-president-and-ceo-dr.-steven-c.-quay-to-speak-at-precision
https://www.nasdaq.com/press-release/covid-19-origin-and-spread-linked-to-pla-hospital-and-wuhan-metro-system-line-2-by
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-pricing-of-%2425.2-million-registered-direct-offering
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-pricing-of-%2414.0-million-registered-direct-offering
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-pricing-of-%2420.0-million-underwritten-public-offering
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-third-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-preliminary-results-from-phase-1-clinical-study-showing
https://www.nasdaq.com/press-release/new-research-points-to-the-peoples-liberation-army-hospital-in-wuhan-china-as-the
https://www.nasdaq.com/press-release/atossa-therapeutics-completes-enrollment-of-phase-1-clinical-study-of-at-301-nasal
https://www.nasdaq.com/press-release/registration-is-now-open-for-atossa-therapeutics-tribe-public-webinar-presentation-0
https://www.nasdaq.com/press-release/physician-scientist-dr.-steven-quay-provides-best-selling-book-stay-safe%3a-a
https://www.nasdaq.com/press-release/atossa-therapeutics-to-present-at-the-oppenheimer-co.-fall-healthcare-life-sciences
https://www.nasdaq.com/press-release/atossa-therapeutics-receives-second-positive-interim-safety-assessment-in-clinical
https://www.nasdaq.com/press-release/physician-scientist-dr.-steven-quays-stay-safe%3a-a-physicians-guide-to-survive
https://www.nasdaq.com/press-release/physician-scientist-dr.-steven-quay-shares-back-to-school-tips-to-stay-safe-and
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-positive-interim-safety-assessment-of-first-group-of
https://www.nasdaq.com/press-release/ld-micro-360-companies-set-to-present-this-week-2020-08-31
https://www.nasdaq.com/press-release/new-covid-19-survival-manual-offers-tips-from-renowned-physician-scientist-to-keep
https://www.nasdaq.com/press-release/atossa-therapeutics-to-present-at-the-ld-micro-500-virtual-conference-on-september-4
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-enrollment-and-dosing-completed-in-first-group-of
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-second-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/ld-micro-announces-preliminary-list-of-presenters-for-the-ld-500-2020-08-05
https://www.nasdaq.com/press-release/atossa-therapeutics-receives-approval-to-open-clinical-study-of-at-301-nasal-spray
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-findings-from-fda-approved-expanded-access-treatment
https://www.nasdaq.com/press-release/registration-is-now-open-for-atossa-therapeutics-tribe-public-webinar-presentation
https://www.nasdaq.com/press-release/atossa-therapeutics-contracts-for-clinical-study-of-at-301-nasal-spray-atossas-second
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-successful-in-vitro-testing-of-nasal-spray-formulation%3a
https://www.nasdaq.com/press-release/atossa-therapeutics-advances-product-development-programs-with-multiple-key-hires-in
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-availability-of-manuscript-on-results-from-in-vitro
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-second-covid-19-therapeutic-development-program-at-301
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-successful-in-vitro-testing-results-of-covid-19-drug%3a
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-first-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-positive-interim-phase-2-data-from-endoxifen-breast
https://www.nasdaq.com/press-release/atossa-therapeutics-receives-fda-feedback-on-two-ongoing-programs-2020-05-07
https://www.nasdaq.com/press-release/atossa-therapeutics-contracts-with-nyc-health-hospitals-metropolitan-for-covid-19
https://www.nasdaq.com/press-release/atossa-therapeutics-seeks-clinical-investigation-approval-from-fda-to-launch-the
https://www.nasdaq.com/press-release/atossa-therapeutics-launches-covid-19-hope-drug-development-program-2020-04-16
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-clinical-progress-2020-04-02
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-fourth-quarter-and-year-end-2019-financial-results-and
https://www.nasdaq.com/press-release/atossa-therapeutics-announces-upcoming-meeting-with-fda-2020-03-13
https://www.nasdaq.com/press-release/atossa-therapeutics-inc.-files-for-swedish-regulatory-approval-to-initiate-a-phase-2
https://www.nasdaq.com/press-release/atossa-therapeutics-inc.-to-present-at-the-22nd-annual-bio-ceo-investor-conference
https://www.nasdaq.com/press-release/atossa-therapeutics-president-and-ceo-dr.-steven-c.-quay-issues-annual-letter-to
https://www.nasdaq.com/press-release/atossa-genetics-announces-phase-2-study-contract-for-oral-endoxifen-to-reduce
https://www.nasdaq.com/press-release/atossa-genetics-to-present-at-the-ld-micro-12th-annual-main-event-on-december-10-2019
https://www.nasdaq.com/press-release/atossa-genetics-announces-third-quarter-2019-financial-results-and-provides-company
https://www.nasdaq.com/press-release/atossa-genetics-to-present-on-october-29th-at-the-5th-annual-dawson-james-small-cap
https://www.nasdaq.com/press-release/atossa-genetics-receives-irb-approval-for-phase-2-breast-cancer-study-using
